Synonym
EM 5519; EM5519; EM-5519; Safracin B; Antibiotic EM 5519; Antibiotic Y 16482-alpha; Antibiotic Y 16482alpha
IUPAC/Chemical Name
Propanamide, 2-amino-N-((6,7,9,10,13,14,14a,15-octahydro-1,7-dihydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,15-imino-5H-isoquino(3,2-b)(3)benzazocin-9-yl)methyl)-
InChi Key
GKUZBRIJGIGFKC-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H36N4O7/c1-11-7-14-8-17-28(37)32-16(21(31(17)4)19(14)23(34)25(11)38-5)9-15-20(18(32)10-30-27(36)13(3)29)24(35)26(39-6)12(2)22(15)33/h7,13,16-18,21,28,34,37H,8-10,29H2,1-6H3,(H,30,36)
SMILES Code
CC(N)C(NCC1C2=C(C(C(C)=C(OC)C2=O)=O)CC3C4C5=C(O)C(OC)=C(C)C=C5CC(N4C)C(O)N31)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
540.62
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ikeda Y, Idemoto H, Hirayama F, Yamamoto K, Iwao K, Asao T, Munakata T. Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation. J Antibiot (Tokyo). 1983 Oct;36(10):1279-83. PubMed PMID: 6417094.
2: Meyers E, Cooper R, Trejo WH, Georgopapadakou N, Sykes RB. EM5519, a new broad-spectrum antibiotic produced by Pseudomonas fluorescens. J Antibiot (Tokyo). 1983 Feb;36(2):190-3. PubMed PMID: 6403499.
3: Ikeda Y, Matsuki H, Ogawa T, Munakata T. Safracins, new antitumor antibiotics. II. Physicochemical properties and chemical structures. J Antibiot (Tokyo). 1983 Oct;36(10):1284-9. PubMed PMID: 6643278.
4: Cooper R, Unger S. Structure of the quinone antibiotic EM5519 and the behavior of quinones in fast atom bombardment mass spectrometry. J Antibiot (Tokyo). 1985 Jan;38(1):24-30. PubMed PMID: 3972725.
5: Ikeda Y, Shimada Y, Honjo K, Okumoto T, Munakata T. Safracins, new antitumor antibiotics. III. Biological activity. J Antibiot (Tokyo). 1983 Oct;36(10):1290-4. PubMed PMID: 6358171.
6: Okumoto T, Kawana M, Nakamura I, Ikeda Y, Isagai K. Activity of safracins A and B, heterocyclic quinone antibiotics, on experimental tumors in mice. J Antibiot (Tokyo). 1985 Jun;38(6):767-71. PubMed PMID: 4019320.
